TNF inhibitors should be used in patients with heart failure only after consideration of other treatment options.

Contra-indicated in patients with a personal or family history of multiple sclerosis or demyelinating disease.

TNF inhibitors should not be administered to patients with moderate to severe heart failure (New York Heart Association Functional Class III/IV).

Infliximab-dyyb (Inflectra) is biosimilar to Infliximab (Remicade). Approved 04/05/2016

Infliximab-abda (Renflexis) is biosimilar to Infliximab (Remicade). Approved 04/21/2017

Infliximab-qbtx (Ixifi) is biosimilar to Infliximab (Remicade). Approved 12/13/2017

Infliximab-axxq (Avsola) is biosimilar to Infliximab (Remicade). Approved 12/06/2019

Infliximab-dyyb (Zymfentra) is biosimilar to Infliximab. Approved 10/20/2023

SERIOUS INFECTIONS and MALIGNANCY

See full prescribing information for complete boxed warning.

Please login to view the rest of this drug profile.

    DRUG REVIEW ARTICLE

    Click on the DRUG REVIEW ARTICLE tab (above) to see a review of infliximab in the Taylor & Francis journal Expert Opinion on Drug Safety.

    (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 06/06/2025

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric